REFERENCES
- Jin, M.; Yang, F.; Yang, I.; Yin, Y.; Luo, J.J.; Wang, H.; Yang, X.F. Uric acid, hyperuricemia and vascular diseases. Front Biosci. (Landmark Ed). 2012, 17, 656–669.
- Kutzing, M.K.; Firestein, B.L. Altered uric acid levels and disease states. J. Pharmacol. Exp. Ther. 2008, 324(1), 1–7.
- Azenabor, A.A.; Hoffman-Goetz, L. Intrathymic and intrasplenic oxidative stress mediates thymocyte and splenocyte damage in acutely exercised mice. J. Appl. Physiol. 1999, 86(6), 1823–1827.
- Hosoyamada, M.; Takiue, Y.; Morisaki, H.; Cheng, J.; Ikawa, M.; Okabe, M.; Morisaki, T.; Ichida, K.; Hosoya, T.; Shibasaki, T. Establishment and analysis of SLC22A12 (URAT1) knockout mouse. Nucleosides Nucleotides Nucleic Acids. 2010, 29(4–6), 314–320.
- Dan, T.; Tanaka, H.; Koga, H. Mechanism of uricosuric action of AA-193 in DBA/2N mice. J. Pharmacol. Exp. Ther. 1990, 253(2), 437–443.
- Al-Khalidi, U.A.; Chaglassian, T.H. The species distribution of xanthine oxidase. Biochem. J. 1965, 97(1), 318–320.
- Tan, S.; Radi, R.; Gaudier, F.; Evans, R.A.; Rivera, A.; Kirk, K.A.; Parks, D.A. Physiologic levels of uric acid inhibit xanthine oxidase in human plasma. Pediatr. Res. 1993, 34(3), 303–307.
- Yonetani, Y.; Douzaki, T.; Ogawa, Y. Epinephrine-induced hyperuricemia in experimental animals. Chem. Pharm. Bull. (Tokyo). 1977, 25(3), 441–447.
- Gothert, M.; Bischoff, D.; Dreyer, C. The influence of inhalation anaesthetics on catecholamine secretion from the adrenal medulla in vivo. Anaesthesist. 1975, 24(1), 19–26.